

## Special Issue

# Drug Resistance and Tumor Microenvironment in Human Cancers

### Message from the Guest Editors

We are calling for manuscripts to be published in the Special Issue 'Drug Resistance and Tumor Microenvironment in Human Cancers' of the Biomedicines journal.

The tumor microenvironment is a critical contributor to triggering the acquisition of drug resistance. This Special Issue aims to collect and publish recent discoveries on the influence of the tumor microenvironment in cancer drug resistance.

Manuscripts describing research on the cellular and molecular basis of resistance to cancer therapy are welcome. Topics may include, but are not limited to, the role of cancer-associated fibroblasts, immune cells, epithelial cells, endothelial cells, acidosis, hypoxia, extracellular matrix proteins and other components of the tumor microenvironment in acquiring drug resistance. Articles identifying novel markers, new therapeutic targets and promising molecular and cellular drug resistance mechanisms will be highly preferred. Original contributions and review articles on this topic are welcomed.

We look forward to receiving your valuable contributions.

### Guest Editors

Dr. Tiago Miguel Amaral Carvalho

Prof. Dr. Silvia Socorro

Dr. Marília Isabel Neto Figueira

### Deadline for manuscript submissions

31 August 2025



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/213814](https://mdpi.com/si/213814)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).